Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
WEEKEND: KNICKS IN 5?
- 15 hours ago
.jpg&w=3840&q=75)
Ishaq Dar and Turkish foreign minister discuss U.S.-Iran progress, express satisfaction
- 4 hours ago
Terrorists based in Afghanistan pose a major threat to the entire Region: the Diplomat
- 4 hours ago
Economic stability has been achieved; government has provided relief to salaried class in the budget, says Atta Tarar
- 2 hours ago
Women’s T20 World Cup: India wins toss and elects to bat first against pakistan
- 2 hours ago
Iran-US peace agreement to be finalized within 24 hours,says Prime Minister Shehbaz Sharif
- a day ago
.jpg&w=3840&q=75)
PM Shehbaz Sharif again invites opposition for dialogue on charter of democracy and charter of economy
- a day ago
Chairman PM Youth Programme assures full support for Punjab University's Film Department.
- a day ago
Key clauses of the proposed U.S.-Iran Agreement revealed
- 4 hours ago
Ishaq Dar’s telephonic contact with Egyptian foreign minister;exchange of views on latest regional situation
- a day ago
Bluesky is getting ‘communities’
- 16 hours ago
PM lauds support of Qatar for Pakistan’s peace efforts
- a day ago
